These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 16467018)
21. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334 [TBL] [Abstract][Full Text] [Related]
23. Puerto Rico psoriasis study group: efficacy and safety of etanercept. González-Chavez JR; Berlingeri-Ramos AC; Sánchez Casiano MA J Drugs Dermatol; 2005; 4(6):735-9. PubMed ID: 16302559 [TBL] [Abstract][Full Text] [Related]
24. [Clinical experience with etanercept in the treatment of psoriasis]. Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167 [TBL] [Abstract][Full Text] [Related]
25. Initial experience with routine administration of etanercept in psoriasis. de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432 [TBL] [Abstract][Full Text] [Related]
26. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. Leonardi C; Strober B; Gottlieb AB; Elewski BE; Ortonne JP; van de Kerkhof P; Chiou CF; Dunn M; Jahreis A J Drugs Dermatol; 2010 Aug; 9(8):928-37. PubMed ID: 20684143 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Nestorov I; Zitnik R; DeVries T; Nakanishi AM; Wang A; Banfield C Br J Clin Pharmacol; 2006 Oct; 62(4):435-45. PubMed ID: 16995864 [TBL] [Abstract][Full Text] [Related]
28. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. Daudén E; Griffiths CE; Ortonne JP; Kragballe K; Molta CT; Robertson D; Pedersen R; Estojak J; Boggs R J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1374-82. PubMed ID: 19563497 [TBL] [Abstract][Full Text] [Related]
30. Etanercept for the treatment of psoriasis: combination therapy with other modalities. Strober BE; Clarke S J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161 [TBL] [Abstract][Full Text] [Related]
31. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Braun J; McHugh N; Singh A; Wajdula JS; Sato R Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658 [TBL] [Abstract][Full Text] [Related]
32. Long-term etanercept in pediatric patients with plaque psoriasis. Paller AS; Siegfried EC; Eichenfield LF; Pariser D; Langley RG; Creamer K; Kricorian G J Am Acad Dermatol; 2010 Nov; 63(5):762-8. PubMed ID: 20605256 [TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413 [TBL] [Abstract][Full Text] [Related]
34. Treatment of erythrodermic psoriasis with etanercept. Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768 [TBL] [Abstract][Full Text] [Related]
36. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A; N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701 [TBL] [Abstract][Full Text] [Related]
37. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. Campione E; Mazzotta A; Paternò EJ; Diluvio L; Prinz JC; Chimenti S Acta Derm Venereol; 2009; 89(3):288-91. PubMed ID: 19479128 [TBL] [Abstract][Full Text] [Related]
38. Our experience with etanercept in the treatment of psoriasis. Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738 [TBL] [Abstract][Full Text] [Related]
39. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. Gottlieb AB; Leonardi CL; Goffe BS; Ortonne JP; van der Kerkhof PC; Zitnik R; Nakanishi A; Jahreis A J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S92-100. PubMed ID: 16488335 [TBL] [Abstract][Full Text] [Related]
40. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S; Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]